Health Care
As pandemic boom fades, Moderna’s market momentum reverses
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market.
Section
Moderna
Company Insights
Moderna, Pfizer Stocks Down Even Amid Rising Covid-19 Cases and Updated Boosters Launch
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.
Moderna
Moderna will ride drug money (and your tax dollars) right out of the red
This time last year, Moderna, Inc., was starting to look a lot like Theranos.
AstraZeneca
Moderna’s trial diversity is all for show if Black and Brown Medicaid recipients can’t afford a vaccine
In the Covid-19 vaccine race, Moderna, Inc. made headlines last week for the representative diversity of its trial candidates.
AstraZeneca
Moderna says vaccine produces antibodies in seniors, pushes ahead in Warp Speed race
Moderna Inc.